HAI Europe calls on EU Commission to consider social aspects of IP directive

4 April 2011

Health Action International (HAI) Europe, a network aiming to increase access to essential medicines, says it has identified numerous shortcomings in the European Commission’s Report and Analysis on the Directive on Intellectual Property (IP) Enforcement, and calls on the Commission to consider the broader social impact of the Directive’s measure, namely access to medicines.

In its response to the consultation on the Report on the IP Enforcement Directive, submitted last week, HAI Europe underlines the Commission’s failure to consider the public health dimension of IP enforcement. Glaring omissions reveal how the analysis process failed to solicit the views of a broad range of stakeholders, namely civil society, while granting business stakeholders multiple opportunities to contribute, it says.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical